China Universal Asset Management Co. Ltd. Has $12.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

China Universal Asset Management Co. Ltd. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,359 shares of the biopharmaceutical company’s stock after selling 3,178 shares during the quarter. Regeneron Pharmaceuticals accounts for about 1.0% of China Universal Asset Management Co. Ltd.’s portfolio, making the stock its 19th biggest position. China Universal Asset Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $12,010,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $226,000. Private Trust Co. NA grew its position in Regeneron Pharmaceuticals by 16.5% in the 2nd quarter. Private Trust Co. NA now owns 191 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 27 shares in the last quarter. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 30.0% in the 2nd quarter. International Assets Investment Management LLC now owns 724 shares of the biopharmaceutical company’s stock valued at $380,000 after buying an additional 167 shares during the last quarter. Finally, Phoenix Financial Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 12.3% during the 2nd quarter. Phoenix Financial Ltd. now owns 583 shares of the biopharmaceutical company’s stock worth $306,000 after buying an additional 64 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on REGN. JPMorgan Chase & Co. upped their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. UBS Group increased their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $793.81.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $782.38 on Friday. The stock has a fifty day moving average of $768.21 and a 200-day moving average of $671.68. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The stock has a market cap of $82.71 billion, a PE ratio of 18.83, a price-to-earnings-growth ratio of 2.13 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the business earned $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue was up 2.5% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 8.47%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 3,636 shares of company stock valued at $2,862,920. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.